0001649094424B5EX-FILING FEESfalsefalseCommon stock, par value $0.001 per sharePre-funded warrants to purchase common stock 0001649094 2024-09-04 2024-09-04 0001649094 1 2024-09-04 2024-09-04 0001649094 2 2024-09-04 2024-09-04 iso4217:USD xbrli:pure xbrli:shares
Exhibit 107
Calculation of Filing Fee Tables
424(b)(5)
(Form Type)
Vaxcyte, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
 
   
Security
Type
 
Security Class
Title
 
Fee
Calculation
or Carry
Forward
Rule
 
Amount
Registered
 
Proposed
Maximum
Offering
Price Per
Unit
 
Maximum

Aggregate
Offering
Price
 
Fee Rate
 
Amount of
Registration
Fee
(1)
Fees to Be
Paid
  Equity  
Common stock,
par value $0.001
per share
  457(r)   14,514,562
(2)
  $103.00   $1,494,999,886   0.00014760   $220,662
Fees to Be
Paid
  Equity  
Pre-funded
warrants to
purchase
common stock
  457(r)   2,427,184   $103.00
(3)
     
(3)
  0.00014760      
(3)
       
Total Offering Amounts 
  $1,494,999,886     $220,662
       
Total Fee Offsets 
     
       
Net Fee
Due 
      $220,662
 
(1)
Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). Payment of the registration fee at the time of filing of the registrant’s Registration Statement on
Form S-3
(File
No. 333-279735)
on May 24, 2024 was deferred pursuant
to
Rules 456(b) and 457(r) under the Securities Act and is paid herewith.
 
(2)
Includes 1,893,203 shares of common stock that the underwriters have an option to purchase and 2,427,184 shares of common stock that are issuable upon the exercise of
pre-funded
warrants referenced below.
 
(3)
Represents the sum of the
pre-funded
warrant sales price of $102.999 per warrant and the exercise price of $0.001 per share issuable pursuant to the
pre-funded
warrants. Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common stock underlying the
pre-funded
warrants.